RIAPANTA 40MG 15TAB

Indications

Approved Uses

Erosive esophagitis associated with GERD (healing) and maintenance of healing; pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).

Off-Label Uses

Common off-label uses include H. pylori eradication as part of combination therapy, prevention of NSAID-associated ulcers in high-risk patients, and stress-ulcer prophylaxis in critically ill patients; other off-label uses include laryngopharyngeal reflux and functional dyspepsia.

Dosage & Administration

Dosing by Condition

Erosive esophagitis (healing): 40 mg PO once daily for up to 8 weeks (may extend to 8 more weeks if needed). Maintenance of healed erosive esophagitis: 40 mg PO once daily. Pathological hypersecretory conditions (e.g., Zollinger-Ellison): 40 mg PO twice daily initially, titrate to control acid output (doses up to 240 mg/day have been used).

Initial Dose

40mg once daily for erosive esophagitis.

Maintenance Dose

20-40 mg once daily

Maximum Dose

240 mg/day (Zollinger-Ellison syndrome); 80 mg/day for standard indications

Children's Dosage

Approved for short-term treatment of erosive esophagitis in children 5 years and older. 15kg to <40kg: 20mg once daily for up to 8 weeks. ≥40kg: 40mg once daily for up to 8 weeks.

Dose Adjustment Notes

Renal impairment: no adjustment. Hepatic impairment: in severe hepatic impairment, consider dose reduction/avoid prolonged high-dose therapy and monitor; for hypersecretory conditions titrate to clinical response. No routine adjustment is recommended solely for CYP2C19 poor metabolizer status.

How to Take

Swallow the 40 mg enteric‑coated (delayed‑release) tablet whole with water; do not crush, chew, or split. Take preferably 30-60 minutes before a meal (often breakfast).

Side Effects

Common Side Effects

Headache, diarrhea, nausea, abdominal pain, flatulence, constipation, vomiting, dizziness

Side Effect Frequency

Common (1-10%): headache, diarrhea, nausea/vomiting, abdominal pain, flatulence, constipation. Uncommon (0.1-1%): dizziness, dry mouth, rash/pruritus, fatigue/asthenia, arthralgia/myalgia, increased liver enzymes. Rare/very rare (<0.1%): interstitial nephritis, hypomagnesemia (often with long-term use), severe cutaneous adverse reactions (e.g., SJS/TEN), lupus erythematosus, severe/persistent diarrhea (C. difficile).

Safety & Warnings

Contraindications

Known hypersensitivity to pantoprazole or other substituted benzimidazoles (e.g., omeprazole, lansoprazole), concomitant use with rilpivirine-containing products.

Warnings & Precautions

Key warnings/precautions: may mask gastric malignancy; long-term use-hypomagnesemia, vitamin B12 deficiency, osteoporosis-related fractures, and C. difficile-associated diarrhea; acute interstitial nephritis; cutaneous/systemic lupus erythematosus (rare); consider pH-related malabsorption issues and monitor as clinically indicated.

Age Restriction

Not approved for children under 5 years of age.

Driving Warning

Safe

Drug Interactions

Drug Interactions

Major/avoid: rilpivirine (contraindicated), atazanavir and nelfinavir (avoid due to reduced absorption/exposure). Important: high-dose methotrexate (consider holding PPI), warfarin (monitor INR), clopidogrel (possible reduced activation-pantoprazole is lower risk than omeprazole but monitor), mycophenolate mofetil (reduced exposure), and drugs needing acidic pH for absorption (e.g., ketoconazole/itraconazole, iron salts).

Interaction Severity

MAJOR/Contraindicated: rilpivirine (avoid). MAJOR/avoid: atazanavir or nelfinavir (reduced antiviral exposure). MODERATE: warfarin (monitor INR), high‑dose methotrexate (consider holding PPI/monitor toxicity), clopidogrel (pantoprazole is preferred among PPIs but monitor/assess risk), drugs needing acidic pH for absorption (e.g., ketoconazole/itraconazole, iron salts).

Food Interaction

Take 30-60 minutes before a meal for best effect; food may delay absorption, so consistent pre‑meal administration is preferred.

Alcohol Interaction

Safe

Special Populations

Pregnancy

Not assigned (Animal reproduction studies have not been conducted with pantoprazole sodium delayed-release tablets. Pantoprazole sodium should be used during pregnancy only if clearly needed.)

Breastfeeding

Caution

Children

Approved for short-term treatment of erosive esophagitis in children 5 years and older. 15kg to <40kg: 20mg once daily for up to 8 weeks. ≥40kg: 40mg once daily for up to 8 weeks.

Elderly

Standard adult dosing; no routine dose adjustment required. Use with caution in elderly patients on long-term therapy due to increased risk of fractures and hypomagnesemia.

Kidney Impairment

No dose adjustment needed for any degree of renal impairment, including hemodialysis

Liver Impairment

Mild-to-moderate hepatic impairment: no adjustment; severe hepatic impairment: do not exceed 20 mg once daily

Storage & Patient Advice

Storage Conditions

Store below 30°C. Keep in original packaging to protect from moisture.

Missed Dose

Take the missed dose as soon as remembered; if it is close to the next dose, skip the missed dose and resume the regular schedule-do not double doses.

Stopping the Medicine

For long-term users, consider tapering to reduce rebound acid hypersecretion; for short-term courses, it is generally safe to stop

Overdose

Limited experience; symptoms are nonspecific (e.g., somnolence/confusion, GI upset, tachycardia, tremor/ataxia reported). Management is supportive/symptomatic; pantoprazole is not significantly removed by hemodialysis; seek urgent medical care/poison center.

Patient Counseling

Take 30-60 minutes before a meal; swallow the enteric‑coated tablet whole (do not crush/chew/split). Use for the prescribed duration; symptom relief may take several days. Seek care for severe/persistent diarrhea, signs of low magnesium (muscle cramps, palpitations), or allergic reactions; discuss long-term risks (e.g., low magnesium, B12 deficiency, fracture risk) if prolonged therapy. Avoid use with rilpivirine and avoid/consult if on atazanavir/nelfinavir; if on warfarin, INR monitoring may be needed.

Monitoring Requirements

Short-term: usually no routine labs. Long-term therapy: consider magnesium periodically (especially if >3 months or with diuretics/digoxin), assess for vitamin B12 deficiency with prolonged use, and monitor INR if on warfarin; monitor for C. difficile-associated diarrhea if persistent diarrhea occurs.

Pharmacology

Mechanism of Action

Prodrug that irreversibly (covalently) inhibits the gastric parietal cell H+/K+-ATPase (proton pump), suppressing basal and stimulated acid secretion.

Onset of Action

Within 1 hour; maximal effect after 2-4 days of once-daily dosing.

Duration of Effect

Approximately 24 hours per dose (once-daily dosing).

Half-Life

Approximately 1 hour (typical range about 1-1.5 hours in healthy adults).

Bioavailability

Approximately 77%.

Metabolism

Hepatic metabolism primarily via CYP2C19 and to a lesser extent CYP3A4; metabolites are not clinically active.

Excretion

Approximately 71% excreted in urine (primarily as metabolites) and ~18% in feces (biliary) after hepatic metabolism.

Protein Binding

Approximately 98%, primarily to albumin.

Product Information

Available Dosage Forms

For RIAPANTA specifically: 40 mg enteric‑coated (delayed‑release) oral tablet. (Pantoprazole in general is also available in some markets as delayed‑release granules/oral suspension and IV injection.)

Composition per Dose

Each enteric-coated tablet: 40 mg pantoprazole as pantoprazole sodium sesquihydrate

Generic Availability

Yes

OTC Alternatives

OTC alternatives (market-dependent) include antacids (aluminum/magnesium hydroxide, calcium carbonate), H2-receptor antagonists (e.g., famotidine), and OTC PPIs such as omeprazole 20 mg (and in some countries pantoprazole 20 mg).

Gi Condition

Acid Reflux/GERD, Ulcer

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.